Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4
Authors' conclusion
Baseline factors associated with a higher likelihood of achieving a BW reduction of ≥15% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, better glycemic status, and lower non-HDL cholesterol. With greater BW reduction, participants with T2D achieved larger improvements in glycemia and cardiometabolic risk parameters. These findings help inform which people with T2D are most likely to achieve greater BW reduction with improved cardiometabolic risk factors with tirzepatide.
Study context
- Population
- Treatment-adherent adults with T2D (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide 5, 10 or 15 mg in SURPASS 1–4treatment-adherent
- Participants
- 3,188 adults
- Comparison
- Categories of body weight (BW) reduction with tirzepatide
- Primary endpoint
- Predictors of BW reduction ≥15% with tirzepatide
- Follow-up
- Week 40/42
Methodological detailspooled analysis of four studies, multivariate model, treatment-adherent participants
- Pooled analysis of four studies
- Multivariate model
- Treatment-adherent participants
Primary result
As reported in the abstract
- Significantly associated with achieving BW reduction ≥15%: higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, and lower baseline HbA1c, fasting serum glucose and non-HDL cholesterol
Further findings
Changes in cardiometabolic parameters by BW reduction category · baseline to week 40/42
- With higher categorical BW reduction, greater reductions in HbA1c, triglycerides, ALT, waist circumference and blood pressure
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →